首页 | 本学科首页   官方微博 | 高级检索  
     

多巴胺D3受体Ser9Gly多态性与利培酮治疗首发精神分裂症患者疗效关系
引用本文:王育红,李文强,郝伟,成爽,谢玲银,张智勇,林永雄,石玉中,郭新胜,师天元,张红亚. 多巴胺D3受体Ser9Gly多态性与利培酮治疗首发精神分裂症患者疗效关系[J]. 中国医药导报, 2012, 0(33): 18-21
作者姓名:王育红  李文强  郝伟  成爽  谢玲银  张智勇  林永雄  石玉中  郭新胜  师天元  张红亚
作者单位:暨南大学附属清远医院精神卫生中心;新乡医学院第二附属医院;中南大学湘雅二医院精神卫生研究所
基金项目:国家十一五重大基础研究与发展项目(2007BAI07B01);973项目(2009CB52000);广东省清远市科技计划项目(2010B92)
摘    要:目的探讨多巴胺D3受体基因多态性与首发精神分裂症患者精神症状严重度和抗精神病药疗效是否相关。方法对201例首发精神分裂症患者进行利培酮治疗[3~5 mg/d,平均(3.2±1.3)mg/d],疗程8周。采用聚合酶链反应限制性片段长度多态性技术检测多巴胺D3受体基因Ser9Gly多态性。并用阳性和阴性症状量表(PANSS)评定患者治疗前和治疗第8周末的精神症状,分析基因型及其他临床指标与PANSS分值和减分率的关系。结果多巴胺D3受体基因Ser9Gly基因型在各患者组分布频率均符合H-W平衡定律(P〉0.05);基因型在治疗显效和未显效组分布频率的差异无统计学意义(χ2=1.995,P=0.369);各基因型亚组临床指标的差异均无统计学意义(均P〉0.05);基因型与患者治疗前PANSS总分(χ2=6.605,P=0.018)、治疗第8周末PANSS总减分率(χ2=6.471,P=0.021)和阳性症状减分率(χ2=6.239,P=0.023)均有统计学意义。结论多巴胺D3受体基因Ser9Gly功能多态性可能影响首发精神分裂症患者对利培酮的治疗效应。

关 键 词:精神分裂症  多巴胺D3受体  Ser9Gly多态性  利培酮

Relationship of efficacy of dopamine D3 receptor Ser9Gly polymorphism and risperidone in the treatment of first episode schizophrenia patients
WANG Yuhong,LI Wenqiang,HAO Wei,CHENG Shuang,XIE Linyin,ZHANG Zhiyong,LIN Yongxiong,SHI Yuzhong,GUO Xinsheng,SHI Tianyuan,ZHANG Hongya. Relationship of efficacy of dopamine D3 receptor Ser9Gly polymorphism and risperidone in the treatment of first episode schizophrenia patients[J]. China Medical Herald, 2012, 0(33): 18-21
Authors:WANG Yuhong  LI Wenqiang  HAO Wei  CHENG Shuang  XIE Linyin  ZHANG Zhiyong  LIN Yongxiong  SHI Yuzhong  GUO Xinsheng  SHI Tianyuan  ZHANG Hongya
Affiliation:1.Mental Health Center of Qingyuan Hospital Affiliated to Ji′nan University,Guangdong Province,Qingyuan 511518,China;2.Institute of Mental Health of Xiangya Second Hospital Affiliated to Central South University,Hu′nan Province,Changsha 410000,China;3.Second Hospital Affiliated to Xinxiang Medical College,He′nan Province,Xinxiang 453000,China
Abstract:Objective To explore the relationship of efficacy of dopamine D3 receptor Ser9Gly polymorphism and risperidone in the treatment of first episode schizophrenia patients.Methods 201 cases of first episode schizophrenia patients were received risperidone treatment [3-5 mg/d,average(3.2±1.3) mg/d],for 8 weeks.The Ser9Gly dopamine D3 receptor gene polymorphism of 201 patients was detected by polymerase chain reaction-restriction fragment length polymorphism.And the psychiatric symptoms of patients before treatment and the treatment of the 8th week was assessed by PANSS.The relationship of genotype and other clinical indicators and PANSS score and reduced rate was analyzed by us.Results Dopamine D3 receptor gene Ser9Gly genotype distribution frequency in each patient group were in line with the HW equilibrium(P 0.05);genotype in the treatment of cured and not cured groups of the frequency difference not statistically significant(χ2 = 1.995,P = 0.369);clinical indicators of each genotype subgroup difference were not statistically significant(P 0.05);genotype with patients before treatment,PANSS total scores(χ2 = 6.605,P = 0.018),PANSS total reduction in treatment at week 8 pointsrate(χ2 = 6.471,P = 0.021) and positive symptom reduction rate(χ2 = 6.239,P = 0.023) were significantly statistically significant.Conclusion Functional polymorphism of the dopamine D3 receptor gene Ser9Gly may affect the first episode schizophrenia treatment effect of risperidone.
Keywords:Schizophrenia  Dopamine D3 receptor  Ser9Gly polymorphism  Risperidone
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号